论文信息 - Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group - 字舞流文

Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group

W. Schmiegel | H. Schmoll | W. Freier | A. Reinacher-Schick | D. Arnold | U. Graeven | S. Kanzler | S. Hegewisch‐Becker | M. Geissler | G. Dietrich